Seiler has been awarded a five-year, $3,823,950 grant from the National Institutes of Health to conduct a preclinical study on rodent models of an innovative co-graft approach to repair permanently damaged retinas.
Jonathan Lakey, Ph.D. (right), and Reza Mohammadi, who earned a doctorate in materials science and engineering at UCI last year while working in Lakey’s lab, helped develop a hybrid alginate that inhibits negative immune responses to pancreatic islet transplantation
“Serious burns can be an incredibly difficult injury to treat and can adversely affect more than just the skin,” said Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research. “This approval provides health care professionals a novel way to treat burn wounds.”
The SCRC flow cytometry core launched its newest instrument, the Helios mass cytometer by Fluidigm. This device combines flow cytometry with mass spectrometry to allow single-cell high parameter protein characterization of cellular identity and function on a level unprecedented at the UCI campus.
UCI Health COVID-19 patient Michael Nguyen was enrolled in a groundbreaking phase 1 clinical trial led by Dr. Leonid Groysman, assistant clinical director of the UCI Alpha Stem Cell Clinic. This was a first-in-human study to evaluate the safety and potential efficacy of natural killer cells to treat patients with moderate COVID-19 disease.
Dr. Acharya and his team will utilize human neural stem cell-derived extracellular vesicles (EVs) to characterize the efficacy and safety to mitigate adverse neurocognitive and neuroinflammatory effects of clinically relevant brain cancer therapies.
The award will support a comprehensive doctoral, postdoctoral and clinical researcher training program to prepare the current and next generation of leaders in stem cell biology, gene therapy, and regenerative medicine.
The SCRC and campus partners have collaborated to complete the renovations, furnishing, and equipment to establish a phase 1 outpatient infusion center on the first floor of Gross Hall where the ASCC team can administer medications and therapeutics in support of stem cell clinical trials.
According to public health expert and SCRC faculty member Leigh Turner, Ph.D., more than four times as many businesses and clinics are selling stem cell products not approved by the U.S. Food and Drug Administration.
Skin, a uniquely observable and diverse organ, has long been the fascination of Plikus, professor of Developmental and Cell Biology. Plikus is developing new ways to help the human body regenerate skin — without scars — by exploring the mechanisms behind tissue repair and stem cell control.
Aileen Anderson, professor of physical medicine & rehabilitation, has been awarded a 30-month, $5.5 million grant from the California Institute for Regenerative Medicine. The funds will be used in the development of a new human neural stem cell therapeutic for treating chronic cervical spinal cord injury.
A key component of the Sue and Bill Gross Stem Cell Research Center is the Stem Cell Core Facility. This facility (the "Core") provides stem cell technology and resources to the UCI, Orange County, and Southern California research communities.